Trial of Early, Goal-Directed Resuscitation for Septic Shock

Paul Mouncey, Tiffany M. Osborn, G. Sarah Power, David A Harrison, Zia Sadique, Richard Grieve, Rahi Jahan, Sheila Harvey, Derek Bell, Julian Bion,

New England Journal of Medicine · 2015 · 1.6K citations · 24 references

DOIFull text

Open access

Concepts

TL;DR

Early, goal‑directed therapy is recommended by international guidelines for resuscitating patients with early septic shock. To evaluate the effectiveness and cost‑effectiveness of EGDT versus usual care in a pragmatic randomized trial across 56 English hospitals. Patients were randomized to a 6‑hour EGDT protocol or usual care, with 1260 participants (630 per arm). EGDT did not reduce 90‑day mortality (29.5% vs 29.2%, RR 1.01, 95% CI 0.85–1.20) and was associated with higher fluid, vasoactive, and transfusion use, worse organ‑failure scores, longer ICU stays, no improvement in secondary outcomes, and higher costs with <20% probability of cost‑effectiveness. The study was funded by the UK National Institute for Health Research Health Technology Assessment Programme (ISRCTN36307479).

Abstract

Early, goal-directed therapy (EGDT) is recommended in international guidelines for the resuscitation of patients presenting with early septic shock. However, adoption has been limited, and uncertainty about its effectiveness remains.We conducted a pragmatic randomized trial with an integrated cost-effectiveness analysis in 56 hospitals in England. Patients were randomly assigned to receive either EGDT (a 6-hour resuscitation protocol) or usual care. The primary clinical outcome was all-cause mortality at 90 days.We enrolled 1260 patients, with 630 assigned to EGDT and 630 to usual care. By 90 days, 184 of 623 patients (29.5%) in the EGDT group and 181 of 620 patients (29.2%) in the usual-care group had died (relative risk in the EGDT group, 1.01; 95% confidence interval [CI], 0.85 to 1.20; P=0.90), for an absolute risk reduction in the EGDT group of -0.3 percentage points (95% CI, -5.4 to 4.7). Increased treatment intensity in the EGDT group was indicated by increased use of intravenous fluids, vasoactive drugs, and red-cell transfusions and reflected by significantly worse organ-failure scores, more days receiving advanced cardiovascular support, and longer stays in the intensive care unit. There were no significant differences in any other secondary outcomes, including health-related quality of life, or in rates of serious adverse events. On average, EGDT increased costs, and the probability that it was cost-effective was below 20%.In patients with septic shock who were identified early and received intravenous antibiotics and adequate fluid resuscitation, hemodynamic management according to a strict EGDT protocol did not lead to an improvement in outcome. (Funded by the United Kingdom National Institute for Health Research Health Technology Assessment Programme; ProMISe Current Controlled Trials number, ISRCTN36307479.).

References

24